Get started
AMGEN INC CEDEAR EACH 30 REP 1AMGEN INC CEDEAR EACH 30 REP 1AMGEN INC CEDEAR EACH 30 REP 1

AMGEN INC CEDEAR EACH 30 REP 1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

AMGN trade ideas

Amgen: False Breakdown and Uptrend?Amgen has been fighting higher this year, and some traders may think a longer-term uptrend is in place. The first pattern on today’s chart is the move under $310 after mixed quarterly results. The drugmaker quickly recovered as Wall Street focused on its pipeline. The resulting drop and rebound could be viewed as a “false breakdown,” which is potentially bullish. Next is the price zone between the closing highs of February and June. AMGN has stayed above that area for almost two weeks. Has old resistance become new support? It’s also holding the rising 50-day simple moving average. That could reflect a bullish intermediate-term trend. Finally, Wilder’s Relative Strength Index (RSI) just crossed above its 14-day average. Similar crossovers have preceded moves in both directions. (See arrows.) TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NASDAQ:AMGN
by TradeStation
AMGN - Increased Probability of AppreciationAMGN has the support of Fiboclouds indicating an increased probability of appreciation at least until the first target. The second target should be tested, provided the stop loss is properly repositioned at the time of the first partial realization. If this projection is confirmed and a partial realization occurs at the first target, the stop loss should be moved from its initial position to the same line where the position was opened. This way, the journey towards the final target will proceed with reduced risk of losses and the preservation of the partial gains achieved so far. Follow us to receive notifications of new trades as well as frequent updates on ongoing trades. Finally, if you agree with the idea or found it useful, please give it a BOOST so that it can reach a larger number of people! Thank you!
NASDAQ:AMGNLong
by EthosInvest
Buyback Patterns for Swing TradingNASDAQ:AMGN shows a buyback run followed by a sell day that was instigated by market makers as buyers quickly disappeared. Remember that corporate buybacks are done by bank floor traders to add stock to their inventory so they won't take profits at the peak of the run; those are other market participants, such as market makers. NYSE:KO is another example of a buyback run and how price moves back down after the professionals conclude their buybacks. The buybacks were announced in May this year so this stock has just started its share repurchase program.
NASDAQ:AMGN
by MarthaStokesCMT-TechniTrader
AMGN Puts 290 Strike August 16th Expiration.I believe "AMGN" will get to around 217.7ish and then dip. From a technical viewpoint I believe its showing a "head and shoulders top" based on a chart that looks back since August of 2023. I am a rookie and don't know if this is true but am basing it on that. From a fundamental viewpoint I believe the stocks rise is all a bunch of garbage. The market is bullish over the weight-loss market and are rushing into any idea in biotech that may work. Its tempting to do this because of how Eli Lilly has been historically strong, while everything else in its sector is basically garbage. My stop loss would be at above 322ish and my profits would start being taken under 300. They report earnings in week of August 1 to August 5. Detail of Potential Trade Enter Target: 317.7 Strike: 290 Expiration: AUG 16th Current Premium as of Publish: 4.2
NASDAQ:AMGNShort
by aminneil43002
Amgen's MariTide Shakes Up Weight Loss Drug MarketThe weight loss drug market, projected to hit $100 billion by the decade's end, is undergoing significant innovation. Amidst dominant players like Novo Nordisk and Eli Lilly, Amgen is emerging with MariTide, a potentially game-changing drug set to disrupt the industry. MariTide's extended-release formula promises reduced dosing frequency and sustained weight loss, potentially outperforming current medications. Amgen's advantage lies in its robust manufacturing infrastructure, enabling efficient scaling compared to smaller competitors. However, the field is crowded, with Novo Nordisk and Eli Lilly developing next-gen drugs, while Boehringer Ingelheim and others introduce new contenders. Smaller biotechs like Viking Therapeutics and Altimmune are also advancing innovative solutions. This competitive landscape promises diverse and effective weight management options for patients. The future looks bright, with Amgen positioned as a strong buy in this evolving market.
NASDAQ:AMGNLong
by signalmastermind
AMGN Rises as CEO Celebrates Growth in Experimental Obesity DrugAmgen Inc.'s shares ( NASDAQ:AMGN ) rose by 15.9% when the market opened on Friday, marking its biggest intraday rise since July 2009. The company has emerged as a potential competitor to Eli Lilly & Co. and Novo Nordisk A/S, which currently dominate the weight-loss market. Demand for anti-obesity drugs like Zepbound and Wegovy is so strong that Intelligence's estimate for $80 billion in annual sales by 2030 looks conservative. William Blair analyst Matt Phipps sees MariTide as having multi-blockbuster potential, boosting his rating on Amgen stock to outperform. Shares of Denmark's Novo Nordisk fell as much as 5.3% after the Amgen CEO's comments. Optimism over towering sales of its Wegovy and Ozempic drugs have pushed Novo's market value above $500 billion, reinforcing its position as Europe's most valuable listed company. The stock has more than quadrupled since the start of 2020. MariTide has excited investors because it's taken less frequently than the top-selling treatments from Novo and Lilly. Patients given a monthly injection of the drug lost up to 14.5% of their body weight in 12 weeks, according to a small early-stage study published in February in the journal Nature Metabolism. Some people kept weight off for up to 150 days after stopping the drug, the findings showed. Amgen ( NASDAQ:AMGN ) is already investing in building out production capacity for MariTide, even though it's still in mid-stage studies and hasn't been submitted for regulatory approval. Amgen is planning late-stage studies in obesity, obesity-related conditions, and diabetes, likely delivered in a handheld autoinjector used monthly. Amgen will focus on MariTide and discontinue developing another earlier-stage drug called AMG 786.
NASDAQ:AMGNLong
by DEXWireNews
Can Amgen(NASD:AMGN) shares go significantly higher?The Minichart Trendline indicator has determined that the share price of Amgen Inc. has just broken its downtrend and is likely to recover from here. This indicator developed by Minichart can detect stocks that change their trend, either from an uptrend to a downtrend or vice versa. It is plotted automatically. First of all, Amgen Inc. stock price reached a short-term support 2 days ago when it hit the 38.2% Fibonacci support of a strong uptrend. The uptrend of the stock price started on 1 June 2023, and lasted for 7 months. The strong uptrend has also formed a bullish head and shoulders (H&S) formation on the Minichart. From a technical analysis perspective, the recent pullback is a salutary correction after the price broke out of the H&S formation. Over time, the price will probably continue to rise and break above the high reached on February 5. In addition, there are 3 other reasons why the price may have reached a good support and could rise again from here. The price has reached the exponential moving average of 100. This is a strong support level. The Minichart Heikin Ashi indicator has changed colour. It is now bullish. The Stochastic indicator is oversold and starting to turn upwards. Amgen Inc. Price Target Next, we will use the Fibonacci retracement to find the immediate price target when the price starts to recover. Using the Minichart Fibonacci retracement measurement from February 5 to 20, the first price target is $299, followed by $305. This is based on the 38.2% to 50% Fibonacci retracement levels. These levels coincided with resistance points during the sideways consolidation (green arrow on the chart). If traders were to buy the stock based on Friday’s close of $289.18, they could potentially realise a decent return of 3.5% to 5.5%. This is based on the $299 to $305 Minichart price target mentioned above. Of course, this is a short-term price target that can be reached within the next few weeks. Should the share price break through the high reached on February 5, the new price target will be significantly higher.
NASDAQ:AMGNLong
by minichartsg
Amgen Poised for Continued Upside## Amgen Poised for Continued Upside Amgen Inc. (AMGN) appears poised for continued upside based on technical indicators. The current price of $324.56 is above the 50-day and 200-day simple moving averages, indicating an upward trend. Key technical indicators also suggest further upside: - Relative Strength Index (RSI) of 66 indicates AMGN is not overbought and has room to run - Moving Average Convergence Divergence (MACD) line recently crossed above the signal line in a bullish sign - Bollinger Bands widening suggests building upside momentum I am initiating a buy on AMGN with an entry point of $330.95. This allows some room above the current price for confirmation of the uptrend. Profit targets are set at $340.79, while a stop loss of $321.36 limits downside risk. The positive technical outlook combined with strong fundamentals makes AMGN a compelling buy at current levels for continued price appreciation. I will look to take profits as the price approaches overbought levels near the upper Bollinger Band. Managing risk with the defined stop loss is also key to success of this long setup. Citations: www.investing.com www.chartmill.com www.macroaxis.com www.tipranks.com financhill.com
NASDAQ:AMGNLong
by decisioncrafters
🔬💊 Amgen Innovations & Strategic Moves 🚀🌟 Lumakras Breakthrough: Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients. 💰 Strategic Acquisition: Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash. Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio. 📈 Market Outlook: Bullish stance on AMGN suggests support levels above $260.00-$265.00. Anticipated upside target in the range of $360.00-$365.00. Exciting developments in biotech and strategic expansion for Amgen! 🌐💉 #AmgenInnovation #Biotech #StockMarket 📰📊
NASDAQ:AMGNLong
by Richtv_official
1
Ascending Triangle in Amgen?Amgen has been stuck at its current price area for almost 3-1/2 years, but now some traders may expect its longer-term uptrend to resume. The first pattern on today’s chart is the $255-260 price zone. It roughly matches peaks in the summer of 2020, the spring of 2021 and the spring of 2022. AMGN ripped through it late last year, pulled back and stalled at the same price area in April of this year. Strong earnings drove the pharma stock above that level in August. It was subsequently tested in September and late October, with prices remaining above. Has old resistance become new support? Second is the series of higher lows since the last dip. The resulting ascending triangle is a potentially bullish continuation pattern. Third, the 50-day simple moving average (SMA) had a “golden cross” above the 200-day SMA in mid-September. That may suggest the longer-term trend is getting more positive. Finally, the lower study features our 2 MA Ratio custom script with the default settings of the 8-day and 21-day exponential moving averages (EMAs). It just turned positive, meaning the faster EMA has risen above slower EMA. That may suggest the shorter-term trend is getting more positive. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more. Important Information Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options, futures or cryptocurrencies); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission (“SEC”) and a futures commission merchant licensed with the Commodity Futures Trading Commission (“CFTC”). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association (“NFA”), and a number of exchanges. TradeStation Crypto, Inc. offers to self-directed investors and traders cryptocurrency brokerage services under federal and state money services business/money-transmitter and similar registrations and licenses. TradeStation Securities, Inc., TradeStation Crypto, Inc., and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., all operating, and providing products and services, under the TradeStation brand and trademark. TradeStation Crypto, Inc. offers to self-directed investors and traders cryptocurrency brokerage services. It is neither licensed with the SEC or the CFTC nor is it a member of NFA. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NASDAQ:AMGN
by TradeStation
AMGN Amgen Options Ahead of Earnings If you haven`t sold AMGN on the HZNP deal: Then analyzing the options chain and the chart patterns of AMGN Amgen prior to the earnings report this week, I would consider purchasing the 262.5usd strike price Puts with an expiration date of 2023-11-17, for a premium of approximately $8.15. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NASDAQ:AMGNShort
by TopgOptions